Regarding combined incretin agents, the ongoing TREASURE study assesses the effects of the GLP-1/GIP receptor agonist tirzepatide on iohexol-measured GFR in people with CKD with or without diabetes (53). This evidence concerns the gene GLP1R and diabetes mellitus.